Dr. Mikhail N Kosiborod and Dr. C. Michael Gibson Discuss: Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial

Disclosure regarding the REALIZE-K Trial:Dr. Mikhail Kosiborod will become an AstraZeneca BioPharmaceuticals Research and Development Employee as Senior Vice President for Late Stage Cardiovascular, Renal and Metabolic Disease, effective January 6th 2025; this role entails development oversight for several compounds, including SZC, which was tested during the REALIZE-K Trial. During conduct of the REALIZE-K Trial, Dr. Mikhail Kosiborod acted as the PI from an independent academic research organization; he was not an employee of AstraZeneca during the design or conduct of REALIZE-K Trial or at the time of manuscript submission.